Researchers at the University of Michigan Rogel Cancer Center have identified a critical genetic mechanism that drives prostate cancer cells toward a more aggressive, treatment-resistant state. By pinpointing a gene known as PROX1, the study offers a potential lifeline for patients whose tumors have evolved to bypass standard hormonal therapies, suggesting that existing classes of drugs could be repurposed to combat these lethal subtypes of the disease.<\/p>\n
The findings, published in the Journal of Clinical Investigation<\/em>, provide a significant breakthrough in understanding "lineage plasticity"\u2014a complex biological process where cancer cells shed their original identity to survive, effectively rendering them immune to conventional treatments that target the androgen receptor.<\/p>\n Prostate cancer has long been treated by targeting the androgen receptor (AR), a protein that drives the growth of most prostate tumors. However, a major hurdle in clinical oncology is the subset of patients whose tumors eventually lose their reliance on this receptor. Once these tumors undergo the process of lineage plasticity, they transition into more aggressive, treatment-resistant forms, such as double-negative prostate cancer or neuroendocrine prostate cancer.<\/p>\n "Patients whose prostate tumors lose reliance on the androgen receptor do poorly," says senior study author Joshi J. Alumkal, M.D., the Wicha Family Professor of Oncology at the University of Michigan Rogel Cancer Center. "Our results suggest a therapeutic approach for patients whose tumors have undergone that shift."<\/p>\n Lineage plasticity is essentially a survival strategy for the cancer. As the tumor cells face the stress of androgen-deprivation therapy, they shift away from their typical glandular identity and adopt alternate, often more resilient, cellular identities. Understanding the molecular drivers of this transition has been a primary objective for cancer researchers, as these aggressive subtypes have historically lacked effective treatment options.<\/p>\n Led by Zhi Duan, Ph.D., the research team embarked on an extensive analysis of patient tumor biopsies to determine what triggers this cellular metamorphosis. Their investigation centered on identifying factors that were uniquely active in tumors undergoing this transition.<\/p>\n The researchers identified the gene PROX1 as the top upregulated factor in tumors that had undergone lineage plasticity. PROX1 is known to play a crucial role in dictating cell identity in both healthy biological development and the chaotic environment of cancer cells. As the study progressed, the team found a clear pattern: as prostate cancer cells shifted to an alternate identity, the expression of PROX1 increased significantly.<\/p>\n To confirm these findings, the team examined hundreds of patient tumor samples across the spectrum of lineage plasticity. They found that PROX1 acted as an early marker for the shift. Crucially, they observed that PROX1 was "turned on" in both double-negative prostate cancer\u2014which lacks androgen receptor activity\u2014and neuroendocrine prostate cancer, which has lost the expression of the receptor entirely.<\/p>\n The inverse correlation was stark: in patient datasets, high levels of PROX1 expression were consistently linked to low levels of androgen receptor expression. To prove the causal relationship, the researchers introduced PROX1 into prostate cancer cells in the laboratory, which subsequently caused the androgen receptor to be turned off.<\/p>\n "We think PROX1 is regulating the androgen receptor," Alumkal explains. "It may be one explanation for why the androgen receptor gets turned off when tumors undergo lineage plasticity and transition away from the typical glandular prostate cancer identity."<\/p>\n Once the team established that PROX1 was a driver of this aggressive transformation, they sought to determine if eliminating the gene could stop the tumor’s growth. Using genetic methods to silence PROX1 in both double-negative and neuroendocrine prostate cancer cells, the researchers observed that the cancer cells stopped proliferating and began to die. This confirmed that targeting PROX1 could be a highly effective strategy for controlling these resistant tumors.<\/p>\n However, the team faced a significant pharmacological hurdle: PROX1 is a transcription factor, a type of protein known for being notoriously difficult to target directly with drugs. Because these proteins function by binding to DNA to turn genes on or off, they lack the traditional "pockets" that most small-molecule drugs use to lock onto and inhibit a protein\u2019s function.<\/p>\n To circumvent this, the researchers looked at the proteins that interact with PROX1\u2014essentially analyzing the company that the protein keeps. Among the primary binding partners for PROX1 were histone deacetylases, or HDACs. <\/p>\n "We felt like this was guilt by association," Alumkal says. "We hypothesized that HDACs might cooperate with PROX1 and that targeting HDACs might be like targeting PROX1."<\/p>\n This was a strategic pivot. HDACs are already well-characterized in cancer research, and several HDAC inhibitors have already been approved by the U.S. Food and Drug Administration (FDA) for use in treating other types of malignancies. By shifting the focus to these existing drugs, the researchers bypassed the need to develop a new, untested therapy from scratch.<\/p>\n The results were promising. In laboratory models, prostate cancer cells that expressed PROX1 proved to be highly sensitive to HDAC inhibitors. When treated with these drugs, the PROX1 protein was depleted, mirroring the results seen when the gene was removed genetically. As the levels of PROX1 dropped, the tumor cells died, suggesting a clear path forward for clinical intervention.<\/p>\n "Our work implicates PROX1 as an important early driver away from androgen receptor dependence," Alumkal notes. "HDAC inhibitors can block PROX1 and reduce survival of aggressive prostate tumor models that have transitioned away from androgen receptor reliance."<\/p>\n The implications for patients are substantial. Currently, individuals diagnosed with neuroendocrine prostate cancer or those whose tumors have become double-negative have very few, if any, effective treatment options. The researchers argue that because HDAC inhibitors are already established in the clinical landscape, they could potentially be moved into clinical trials for these specific, high-risk prostate cancer subtypes relatively quickly.<\/p>\n "Our results suggest this class of drugs should be prioritized for clinical trials in patients who have aggressive prostate cancer subtypes, for which there are few treatment options," Alumkal said.<\/p>\n The study involved a broad collaboration of experts, with additional authors including Mingchen Shi, Anbarasu Kumaraswamy, Dong Lin, Dhruv Khokhani, Yong Wang, Chao Zhang, Fiana Flores, Eva Rodansky, Olivia A. Swaim, William K. Storck, Hannah Beck, Radhika A. Patel, Erolcan Sayar, Brian P. Hanratty, Hui Xue, Xin Dong, Zoe R. Maylin, Rensheng Wan, David A. Quigley, Martin Sjostrom, Ya-Mei Hu, Faming Zhao, Zheng Xia, Siyuan Cheng, Xiuping Yu, Felix Y. Feng, Li Zhang, Rahul Aggarwal, Eric J. Small, Visweswaran Ravikumar, Arvind Rao, Karan Bedi, John K. Lee, Colm Morrissey, Ilsa Coleman, Peter S. Nelson, Eva Corey, Aaron Udager, Ryan Rebernick, Marcin P. Cieslik, Arul M. Chinnaiyan, Joel A. Yates, Michael C. Haffner, and Yuzhuo Wang.<\/p>\n The research received extensive funding from multiple institutions, including the National Institutes of Health, the U.S. Department of Defense, the Prostate Cancer Foundation, the Canadian Institutes of Health Research, the Terry Fox Research Institute, and several other private and public research foundations, reflecting the high priority placed on solving the puzzle of treatment-resistant prostate cancer. By successfully identifying PROX1 as a vulnerable target, this study provides a new, evidence-based direction for clinical oncologists aiming to extend and improve the lives of patients facing the most challenging forms of this disease.<\/p>\n","protected":false},"excerpt":{"rendered":" Researchers at the University of Michigan Rogel Cancer Center have identified a critical genetic mechanism that drives prostate cancer cells toward a more aggressive, treatment-resistant state. By pinpointing a gene known as PROX1, the study offers a potential lifeline for patients whose tumors have evolved to bypass standard hormonal therapies, suggesting that existing classes of […]<\/p>\n","protected":false},"author":1,"featured_media":1289,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[650],"tags":[1168,652,2242,451,2241,1607,2246,2247,2245,678,2244,2248,2243,651],"class_list":["post-1290","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-and-wellness","tag-cancer","tag-fitness","tag-genetic","tag-health","tag-identifies","tag-offering","tag-path","tag-potential","tag-prostate","tag-research","tag-resistant","tag-therapies","tag-treatment","tag-wellness"],"_links":{"self":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts\/1290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1290"}],"version-history":[{"count":0,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts\/1290\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/media\/1289"}],"wp:attachment":[{"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}The Challenge of Lineage Plasticity<\/h3>\n
Unmasking PROX1 as a Genetic Driver<\/h3>\n
Finding a Therapeutic Workaround<\/h3>\n
Clinical Implications for Aggressive Subtypes<\/h3>\n